Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Management’s Priority

<< Previous

Bullboard Posts

Next >>

Comment by Cb27743on Aug 09, 2024 11:03pm

72 Views

Post# 36172530

RE:Management’s Priority

Unplug your keyboard, put down the booze and pick a lane. One minute you love the stock and next minute you hate the stock. We haven't received a return on our investment in years. We get it. Going on rants publicly and having a jammer doesn't help the situation.

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1